Welcome to our dedicated page for Compass Therapeutics SEC filings (Ticker: CMPX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Compass Therapeutics, Inc. filings document a clinical-stage oncology biopharmaceutical company developing proprietary antibody-based therapeutics. Its SEC reports include Form 8-K disclosures for operating and financial results, Regulation FD updates, clinical data presentations and other material events related to tovecimig and the broader antibody pipeline.
The company’s definitive proxy materials cover annual meeting matters, director elections and stockholder voting procedures. Filing disclosures also address governance, equity compensation, capital-structure matters, cash resources, clinical and regulatory risk areas, and the public-company controls associated with a Nasdaq-listed development-stage biotechnology issuer.
Compass Therapeutics has called its 2026 Annual Meeting for June 10, 2026 as a virtual-only event, open to stockholders of record as of April 15, 2026. Holders of 180,087,915 common shares may vote online, by phone, or by mail.
Stockholders will elect two Class III directors, vote on ratifying CohnReznick LLP as auditor for 2026, and cast non-binding advisory votes on 2025 executive pay and how often future “Say‑on‑Pay” votes should occur, with the board recommending an annual frequency.
The filing details board and committee structures, updated 2026 director retainers and option grants, and 2025 compensation for key executives, including total pay of $5.10 million for CEO Thomas J. Schuetz, $1.39 million for CFO Barry Shin, and $1.43 million for General Counsel Jonathan Anderman.
Compass Therapeutics reported detailed results from its randomized Phase 2/3 COMPANION-002 study of tovecimig plus paclitaxel in second-line biliary tract cancer. In 168 patients randomized 2:1, the combination improved overall response rate to 17.1% versus 5.3% for paclitaxel alone, meeting the primary endpoint with statistical significance (p=0.031).
The key secondary endpoint of median progression-free survival also favored tovecimig, with 4.7 months versus 2.6 months for control (hazard ratio 0.44, p<0.0001), based on blinded independent central review. Overall survival analyses did not meet statistical significance because 54% of control patients crossed over to receive tovecimig; these crossover patients showed median overall survival of 12.8 months versus 6.1 months for non-crossover patients (hazard ratio 0.54, p=0.04).
The company stated that tovecimig was generally well tolerated, with a safety profile consistent with prior studies, and noted that 85% of trial participants received the combination. Compass intends to meet with the U.S. FDA in the coming months to discuss the data in advance of a planned Biologics License Application submission for tovecimig in this setting.
Compass Therapeutics, Inc. files its annual report describing a clinical-stage oncology pipeline centered on antibody-based therapies targeting angiogenesis and immune checkpoints. The company highlights four clinical product candidates: tovecimig, CTX-471, CTX-8371 and CTX-10726.
Tovecimig, a DLL4 x VEGF-A bispecific, met the primary endpoint in a randomized Phase 2/3 biliary tract cancer trial, with a 17.1% overall response rate in combination with paclitaxel versus 5.3% for paclitaxel alone, and a statistically significant p-value of 0.031. Additional progression-free and overall survival data are expected in April 2026.
Monotherapy data in metastatic colorectal cancer showed a 5% response rate and 68% disease control. CTX-471, a CD137 agonist, produced responses in heavily pretreated patients and identified NCAM as a potential biomarker, with a Phase 2 basket study planned for mid-2026. CTX-8371, a PD-1 x PD-L1 bispecific, generated deep responses in a Phase 1 trial without dose-limiting toxicities, and expansion cohorts in NSCLC, TNBC and Hodgkin lymphoma are enrolling. CTX-10726, a PD-1 x VEGF-A bispecific, received FDA IND clearance and is entering a Phase 1 dose-escalation study.
Compass Therapeutics reported full-year 2025 results and a broad pipeline update. Net loss was $66.5 million, or $0.42 per share, compared with $49.4 million, or $0.36 per share, in 2024. Research and development expenses rose to $56.0 million, up 32%, mainly from higher manufacturing spend for tovecimig and CTX-10726.
As of December 31, 2025, cash and marketable securities totaled $209 million, up from $127 million a year earlier, giving an expected cash runway into 2028. The company used $49 million in operating cash during 2025, offset by $129 million in net proceeds from an underwritten public offering.
Clinically, lead asset tovecimig met the primary endpoint in the COMPANION-002 Phase 2/3 biliary tract cancer study, with progression-free survival and overall survival analyses expected in April. Expansion cohorts for CTX-8371, IND clearance and Phase 1 initiation for CTX-10726, and a planned Phase 2 trial for CTX-471 position 2026 as an important development year.
Compass Therapeutics, Inc. (CMPX) received an amended Schedule 13G from a group of Blackstone-related entities reporting a reduced ownership position. As of December 31, 2025, the reporting group beneficially owned an aggregate 6,126,182 shares of common stock, representing 3.4% of the class, based on 177,572,498 shares outstanding as of September 30, 2025. Blackstone Annex Master Fund L.P. directly holds 2,447,820 shares, and Spruce Street Aggregator L.P. directly holds 3,678,362 shares. The filing states that, as of that date, the reporting persons no longer beneficially own more than five percent of Compass Therapeutics’ common stock and describes this as an exit filing. The group also certifies that the securities were not acquired to change or influence control of the company and includes standard disclaimers that certain parties may be deemed beneficial owners only through their control of the direct holders.
Compass Therapeutics, Inc. chief executive officer and director Thomas J. Schuetz reported a Form 4 transaction involving company common stock. On 02/08/2026, 36,687 shares of common stock were withheld by the issuer at $6.52 per share to cover tax withholding obligations tied to vesting restricted stock units.
After this tax withholding, Schuetz beneficially owns 6,603,336 shares of common stock. This includes unvested RSUs: 125,000 shares from a February 8, 2023 grant vesting in four equal annual installments starting February 8, 2024; 318,750 shares from a January 9, 2024 grant vesting annually starting January 9, 2025; and 250,000 shares from a January 2, 2026 grant vesting annually starting January 2, 2027.
Compass Therapeutics, Inc. (CMPX) reported that BlackRock, Inc. has filed a Schedule 13G indicating a passive ownership stake in the company’s common stock. BlackRock reports beneficial ownership of 9,271,644 shares of Compass Therapeutics common stock, representing 5.2% of the outstanding class as of the reported date.
BlackRock has sole voting power over 9,138,337 shares and sole dispositive power over 9,271,644 shares, with no shared voting or dispositive power. The filing states that the securities are held in the ordinary course of business and are not intended to change or influence control of Compass Therapeutics. Various underlying clients and accounts have rights to dividends or sale proceeds, but no single one has more than five percent of the total outstanding shares.
Compass Therapeutics, Inc. chief executive officer and director Thomas J. Schuetz reported an automatic share withholding related to equity compensation. On January 9, 2026, 46,777 shares of common stock were withheld by the company at $5.35 per share to cover tax obligations arising from the vesting of restricted stock units. After this tax withholding, Schuetz beneficially owned 6,640,023 shares of common stock.
The filing also notes unvested restricted stock units: 250,000 RSUs from a February 8, 2023 grant, 318,750 RSUs from a January 9, 2024 grant, and 250,000 RSUs from a January 2, 2026 grant. Each award vests in four equal annual installments, with first vesting dates in 2024, 2025, and 2027, respectively.
Compass Therapeutics, Inc. (CMPX) reported an insider ownership update for Chief Executive Officer and Director Thomas J. Schuetz. On 11/16/2025, 44,025 shares of common stock were withheld at a price of $4.83 per share to cover tax obligations arising from the vesting of restricted stock units (RSUs). After this tax withholding transaction, Schuetz beneficially owns 6,436,800 shares of Compass Therapeutics common stock.
The filing notes that 250,000 of these shares relate to unvested RSUs granted on February 8, 2023, which vest in four equal annual installments starting on February 8, 2024. An additional 478,125 shares relate to unvested RSUs granted on January 9, 2024, also vesting in four equal annual installments beginning on January 9, 2025. Each RSU represents a contingent right to receive one share of common stock, subject to continued service-based vesting conditions.